Cancer-EX

Cancer-EX is at the forefront of biotechnology research, dedicated to advancing innovative solutions in the fight against cancer. With a focus on early detection and non-invasive diagnostics, Cancer-EX is developing a Lateral Flow Assay based test that uses saliva to detect target biomarkers, offering a cost-effective and accessible alternative to traditional methods.

Cancer-EX's groundbreaking approach promises to significantly reduce the financial burden and invasiveness associated with current cancer detection techniques. By providing a test that is potentially 1000 times less expensive than MRI and 90 times less expensive than blood tests for Pancreatic Cancer, Cancer-EX aims to make early diagnosis more accessible to a wider population. This innovative technology has the potential to revolutionize cancer screening and improve patient outcomes.

Cancer-EX is committed to driving progress in biotechnology and making a tangible difference in the lives of those affected by cancer. We are rapidly expanding our efforts, and this information will be completed soon with the support of Cancer-EX’s management.

Manager, we invite you to create a customized and exclusive company showcase and product listing on our platform.